GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (HKSE:06955) » Definitions » Net Income

Shandong Boan Biotechnology Co (HKSE:06955) Net Income : HK$-130.6 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Shandong Boan Biotechnology Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Shandong Boan Biotechnology Co's Net Income for the six months ended in Dec. 2023 was HK$0.1 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-130.6 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Shandong Boan Biotechnology Co's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$0.00.


Shandong Boan Biotechnology Co Net Income Historical Data

The historical data trend for Shandong Boan Biotechnology Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co Net Income Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income
-285.14 -276.02 -370.47 -130.57

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Get a 7-Day Free Trial -119.37 -179.69 -199.28 -130.72 0.15

Shandong Boan Biotechnology Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Shandong Boan Biotechnology Co's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-130.572+0+0+0
=-130.6

Shandong Boan Biotechnology Co's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.113+0.261+0+0.00099999999999997
=0.1

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-130.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Boan Biotechnology Co  (HKSE:06955) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Shandong Boan Biotechnology Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Shandong Boan Biotechnology Co Net Income Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Boan Biotechnology Co (HKSE:06955) Business Description

Traded in Other Exchanges
Address
No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
Executives
Asiapharm Investments Ltd.
Ginkgo (ptc) Limited
Liu Dianbo
Luye Life Sciences Group Ltd
Luye Pharma Holdings Ltd.
Luye Pharma Hong Kong Limited
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited
Shorea Lbg
Luye Pharma Group Ltd.
Shan Dong Lv Ye Zhi Yao You Xian Gong Si
Yan Tai Lv Ye Yi Yao Kong Gu Ji Tuan You Xian Gong Si
Li Li 2201 Interest of corporation controlled by you

Shandong Boan Biotechnology Co (HKSE:06955) Headlines

No Headlines